Renato Lenzi, M.D.
Department of General Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Inpatient Medical Director, Inpatient Consult Service, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Professor, General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1977 | Catholic University, Rome, IT, MD |
Postgraduate Training
| 2024-2024 | Practical Improvement Science in Healthcare Certification, Harvard University, Cambridge, MA |
| 2023-2023 | Exercising Leadership: Foundational Principles Certification, Harvard University, Cambridge, Massachusetts |
| 2020-2020 | LEADing Teams Core Curriculum Certification, MD Anderson Leadership Institute, Houston, Texas |
| 2020-2020 | Lean Specialized Credential eLearning Certification, American Society for Quality, Houston, Texas |
| 2020-2020 | Lean Six Sigma eLearning Certification, Yellow Belt, QI Macros (KnowWare International, Inc.), Austin, Texas |
| 2019-2020 | LEADing Teams Certification, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2019-2019 | Clinical Safety and Effectiveness Program Certification, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2014-2015 | Executive Healthcare Administration Certification, Rice University, Houston, Texas |
| 2012-2012 | Faculty Leadership Academy, UT MD Anderson Cancer Center, Houston |
| 2006-2006 | The Heart of Leadership, UT MD Anderson Cancer Center, Houston, Texas |
| 1999-2001 | Faculty in Training, American Academy of Physician and Patient, Houston, Texas |
| 1989-1990 | Clinical Fellowship, Medical Oncology, University of Texas, Houston, Texas |
| 1986-1989 | Research Fellowship, Hematology, The Mount Sinai Hospital Mount Sinai School of Medicine, New York, New York |
| 1985-1986 | Chief Fellow, Hematology, The Mount Sinai Hospital Mount Sinai School of Medicine, New York |
| 1983-1985 | Clinical Fellowship, Hematology, The Mount Sinai Hospital Mount Sinai School of Medicine, New York, New York |
| 1980-1983 | Clinical Residency, Internal Medicine, The Jewish Hospital and Medical Center of Brooklyn, Brooklyn, New York |
| 1978-1980 | Clinical Fellowship, Hematology, The Policlinico Gemelli Hospital, Rome |
| 1977-1978 | Clinical Residency, Internal Medicine, The Policlinico Gemelli Hospital, Rome |
Licenses & Certifications
| 2026 | Texas State Board of Medical Examiners |
| 2023 | Mississippi State Board of Medical Licensure |
| 2023 | Arizona Board of Medical Examiners |
| 2023 | Tennessee Department of Health Division of Health Related Boards |
| 2023 | Alabama Board of Medical Examiners |
| 2023 | Louisiana State Board of Medical Examiners |
| 2023 | Washington State Department of Health |
| 2023 | Oklahoma State Board of Medical Licensure |
| 2021 | Florida Board of Medicine |
| 2013 | American Board of Medical Quality |
| 1991 | American Board of Internal Medicine Medical Oncology |
| 1990 | Texas State Board of Medical Examiners |
| 1986 | American Board of Internal Medicine Hematology |
| 1983 | American Board of Internal Medicine |
Experience & Service
Faculty Academic Appointments
Professor, General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - 2024
Associate Professor, General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2019
Clinical Medical Director, International Assessment Center, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - 2024
Clinical Associate Professor, Gastrointestinal (GI) Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2006 - 2017
Associate Professor, Gastrointestinal (GI) Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, MT, 1998 - 2006
Assistant Professor, Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 1996 - 1998
Assistant Professor, Clinical Investigation, The University of Texas MD Anderson Cancer Center, Houston, 1992 - 1998
Faculty Associate, Clinical Investigation, The University of Texas MD Anderson Cancer Center, Houston, TX, 1990 - 1992
Assistant Attending Physician, Hematology, Mount Sanai Services at Elmhurst, Elmhurst, NY, 1989
Administrative Appointments/Responsibilities
Medical Director Inpatient Consult Service, General Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2025 - Present
Practitioner Peer Assistance Program Manager, General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - Present
Patient Experience Officer, General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - Present
Clinical Medical Director, International Center, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - Present
Physician Auditor, Office of Protocol Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2002
Committee Chair, Gastrointestinal (GI) Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2001 - 2002
Quality Improvement Reviewer, Gastrointestinal (GI) Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1999 - 2002
Other Professional Positions
MD Anderson Group Member, United States Cooperative for International Patients Programs, Houston, TX, 2019 - Present
Planning Committee Member, ASCO Doctor/Patient Communication Skills Workshop, New Orleans, LA, 2004
Member, National Comprehensive Cancer Network Occult Primary Panel, Plymouth Meeting, PA, 2003 - Present
Occult Primary Guideline Panel Member, National Comprehensive Cancer Network, Houston, TX, 2003 - Present
Faculty, Academy of Communication in Healthcare, Houston, TX, 2002 - Present
Quality Monitoring Committee, Department of Gastrointestinal Medical Oncology, Houston, TX, 2001 - 2002
Member, UTHHSC/MDACC Graduate School of Biomedical Sciences Supervisory Committee for Graduate Student, Houston, TX, 2000 - 2001
Quality Improvement Reviewer, Department of Gastrointestinal Medical Oncology, Houston, TX, 1999 - 2002
Member, National Comprehensive Cancer Network Patient/Physician Communication Task Force, Houston, TX, 1999 - 2001
Member, Board of Advisors, SEEDS for SIDS Foundations, Florence, 1998 - 1999
Extramural Institutional Committee Activities
Member, Ascending Senior Faculty Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present
Member, International Virtual Care Innovation Working Group, The University of Texas MD Anderson Cancer Center, 2023 - Present
Member, QAPI Ambulatory Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present
Member, International Virtual Care Innovation Small Working Group, The University of Texas MD Anderson Cancer Center, 2021 - 2022
Member, MD Anderson International Patients Working Group, The University of Texas MD Anderson Cancer Center, 2014 - 2014
Alternate Representative, IRB for Gastrointestinal Department, The University of Texas MD Anderson Cancer Center, 2004 - 2005
Physician Auditor, Office of Protocol Research, The University of Texas MD Anderson Cancer Center, 2002
Chair, GI Care Center Quality Monitoring Committee, The University of Texas MD Anderson Cancer Center, 2001 - 2002
Member, Clinical and Translational Research Center Review Committee, The University of Texas MD Anderson Cancer Center, 2001 - 2002
Member, UTHHSC/MDACC Graduate School of Biomedical Sciences Supervisory Committee, The University of Texas MD Anderson Cancer Center, 2000
Reviewer, Department of GI Quality Improvement, The University of Texas MD Anderson Cancer Center, 1999 - 2002
Member, CORE System Advisory Subcommittee, The University of Texas MD Anderson Cancer Center, 1999 - 2000
Member, Committee For Behavioral Psychosocial and Services Research, The University of Texas MD Anderson Cancer Center, 1996 - 1999
Honors & Awards
| 2005 - 2014 | The Best Doctors in America |
| 2003 - 2018 | America's Top Doctors |
| 2002 - 2018 | Faculty, Academy of Communication in Healthcare |
| 1999 | Shannon Award, National Cancer Institute |
| 1998 | Fellow, American College of Physicians |
| 1985 - 1986 | Chief Fellow in Hematology, Mount Sinai Hospital and Medical Center |
| 1977 | MD, Cum Laude, Catholic University of Rome |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2013. Expressing Wishes for Healthcare from the Perspective of a Physician who is also a Patient. Conference. M.D. Anderson Cancer Center. Houston, TX, US.
- 2000. Communicating Bad News: Proposed Trial. Conference. CCOP Annual Meeting. Houston, TX, US.
- 1999. Managing Patient reactions to Illness. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 1999. Carcinoma of Unknown Primary. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 1998. Carcinoma with Unknown Primary. Conference. St. Joseph Hospital. Houston, TX, US.
- 1998. 2nd Human Cancer Immunotherapy Retreat on Cytokines, Interleukin-12. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 1998. Intraperitoneal Based Immunotherapy for Malignancies of the Peritoneal Cavity, A Novel Intraperitoneal Trial with rhiL-12. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 1998. A Comprehensive Review: Unknown Primary Carcinoma. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 1998. Fundamentals of Therapy of Pancreatic Cancer. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 1998. Metastatic Carcinomas of Unknown Primary. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 1997. Pancreatic Cancer: A review. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 1997. Breast Cancer: Treatment Options and Outcomes. Conference. Free Clinic for Women. Houston, TX, US.
- 1996. New concepts in management and research in patients with metastatic tumors of unknown primary. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 1996. Unknown Primary Carcinomas. Conference. National Youth Leadership Forum. Houston, TX, US.
- 1996. Breast Cancer: Natural History and Treatment Outcomes. Conference. Free Clinic for Women. Houston, TX, US.
Regional Presentations
- 2001. Helping Doctors Deal with Emotional Aspects of Mortality, "Emotional Experiences of Doctors During End-of-Life Care". Conference. Academy of Psychosomatic Medicine. San Antonio, TX, US.
- 2001. New Approaches to Old Problems in Cancer Management, "Carcinomas of Unknown Primary Site". Conference. Texas Health Resources. Arlington, TX, US.
- 2000. Protocol Design Meeting. Conference. Daichi Pharmaceuticals, Inc. Barcelona, ES.
- 2000. Protocol Design Meeting. Conference. MGI Pharma, Inc. Tucson, AZ, US.
- 2000. Protocol Design Meeting. Conference. Daichi Pharmaceuticals, Inc. Chicago, IL, US.
- 2000. Meeting of the Patient/Physician Communication Task Force. Conference. The National Comprehensive Cancer Network. Chicago, IL, US.
- 2000. The Bad News Discussion-Effective Strategies for Communicating the Diagnosis, Prognosis and End of Life Issues. Conference. American Society of Clinical Oncology Annual Meeting. New Orleans, LA, US.
- 2000. Breaking Bad News Workshop. Conference. Texas Medical Association. San Antonio, TX, US.
- 1999. Meeting of the Patient/Physician Communication Task Force. Conference. The National Comprehensive Cancer Network. Chicago, IL, US.
- 1999. Meeting of the Patient/Physician Communication Task Force. Conference. The National Comprehensive Cancer Network. Chicago, IL, US.
- 1999. Protocol Design Meeting. Conference. TAP Pharmaceuticals, Inc. Chicago, IL, US.
- 1999. Expanding the Center: Moving from patient-Centered to Relationship-Centered Care. Conference. American Academy on Physician and Patient, US.
- 1999. Breaking Bad News. Conference. American Academy on Physician and Patient, US.
- 1998. Practical Palliative Medicine: A Skill-Building Workshop on End-of-Life Care. Conference. The University of Texas Medical Branch at Galveston. Galveston, TX, US.
National Presentations
- 1999. Intraperitoneal (IP) bioimmunologic responses in patients with ovarian and gastrointestinal cancers at a low toxicity dosing schedule of IP recombinant interleukin-12 (rhll-12). Invited. American Association for Cancer Research Annual Meeting. Philadelphia, PA, US.
- 1994. The metastatic potential of human melanoma cell lines in independent of p53 mutations in exxons 5-9. Invited. American Association for Cancer Research Annual Meeting, US.
- 1994. Oval cells are not the precursors of hepatocellular carcinoma induced by ethionine feeding in SD rats. Invited. American Association for Cancer Research Annual Meeting, US.
- 1993. Artificial intelligence (neural networks) and discriminate analysis in the evaluation of neuropsychological abnormalities in cancer patients. Invited. American Association for Cancer Research Annual Meeting, US.
- 1992. Reversal of cisplatinum (Cddp) resistance by 5-Aza-2'-Deoxycytidine (DAC) in human ovarian cell lines. Invited. American Association for Cancer Research Annual Meeting, US.
- 1989. Glucose-6-phosphatase (G-6-P) activity is present in hyperplastic, as well as preneoplastic, bile duct-like (oval) cells. Invited. American Association for the Study of Liver Disease Annual Meeting, US.
- 1988. Histologic Immunohistochemical and Functional Characteristics of Oval Cells During Chemical Hepatocarcinogenesis. Invited. American Association for the Study of Liver Disease Annual Meeting, US.
- 1988. Proliferation of bile duct-like structures int he rat: An experimental strategy to study transport function of the intrahepatic biliary epithelium. Invited. American Gastroenterology Association Annual Meeting, US.
- 1987. Transport properly and antigenic end enzymatic phenotypes of proliferative bile duct-like cells in carcinogen and non-carcinogen fed rats. Invited. American Association for the Study of Liver Disease Annual Meeting, US.
- 1986. Immunolocalization of von Willebrand factor in rat liver vascular endothelial cells. Invited. American Association for the Study of Liver Disease Annual Meeting, US.
- 1986. Characterization of factor VII and von Willebrand factors inhibitors absorbed on protein A staphylococci: loss of time dependency and blocking of hemophilic plasma. Invited. ASH Annual Meeting, US.
International Presentations
- 2016. Medical Tourism: The Globalization of Healthcare. Conference. Medical World Americas. Houston, US.
- 2000. The difficult task of breaking bad news: Oncologist's attitudes, practices and challenges. Invited. American Society of Clinical Oncology Annual Meeting. New Orleans, US.
- 1999. Recombinant human interlukin-12 (rhl12) in patients with ovarian and gastrointestinal cancers. Evidence of biological activity and lack of significant toxicity with low-dose intraperitoneal (IP) administration. Invited. American Society of Clinical Oncology Annual Meeting. Atlanta, US.
- 1996. Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Invited. American Society of Clinical Oncology Annual Meeting, US.
- 1994. Poorly differentiated (PDC) and undifferentiated (UDC) carcinomas of unknown primary (UP): Incidence of favorable subsets, response to chemotherapy and survival. Invited. American Society of Clinical Oncology Annual Meeting, US.
Formal Peers
- 1999. Protocol Design Meeting. Invited. Boston, MA, US.
- 1999. Breaking Bad News. Visiting. Boston, MA, US.
- 1998. Carcinoma of the Unknown Primary. Invited. Coronado, CA, US.
- 1998. Communication in Health Care, teaching Communication Skills in Health Care: Three Education Approaches. Visiting. Amsterdam, NL.
Grant & Contract Support
| Date: | 2013 - 2017 |
| Title: | Retrospective Study to Evaluate Variables Predicting No-Show International Patients |
| Funding Source: | MD Anderson Cancer Center Donor Funds |
| Role: | PI |
| Date: | 2005 |
| Title: | A Study of Gene Profiling Validation for Cancer Classification Using Known Primary Carcinoma Samples |
| Funding Source: | Biotheranostics |
| Role: | Collaborator |
| Date: | 2004 - 2006 |
| Title: | Communication between Patients and their Providers |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R-03 CA110791- 01 |
| Date: | 2003 - 2004 |
| Title: | A Study of Psychological Adjustment and Quality of Life of Patients with Pancreatic Cancer |
| Funding Source: | The University of Texas MD Anderson Cancer Center Institutional Research |
| Role: | Co-PI |
| Date: | 2003 - 2008 |
| Title: | Influence of Uncertainty and Communication on Adjustment, Career Development Award |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | 1K-07 CA093562 01 A2 |
| Date: | 2001 - 2002 |
| Title: | An Evaluation of the efficacy and safety of PEG-Camptothecin in the treatment of locally advanced and metastatic carcinoma of the pancreas |
| Funding Source: | Enzon, Inc |
| Role: | PI |
| ID: | DM01-431 |
| Date: | 2001 |
| Title: | A Phase II Study of Intraperitoneal Recombinant Human Interleukin 12 (RHIL-12) in Patients with Peritoneal Carcinomatosis (Residual Disease <1cm) Associated with Ovarian Epithelial or Primary Peritoneal Carcinoma |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Date: | 2001 |
| Title: | A study of uncertainty and of psychosocial adjustment of patients with metastatic cancer of unknown primary |
| Funding Source: | University Cancer Foundation, MDACC |
| Role: | Principal Investigator-MDACC |
| Date: | 1998 - 2000 |
| Title: | Shannon Award |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1 R55 CA77241-01 |
| Date: | 1996 - 1999 |
| Title: | A randomized phase II comparison of two different infusion regimens of gemcitabine therapy in patients with locally advanced or metastatic carcinoma of the pancreas |
| Funding Source: | Eli Lilly and Company |
| Role: | PI |
| ID: | B9E-MC-JHFN CS96-116 |
Selected Publications
Peer-Reviewed Articles
- Hassan MM, Botrus G, Abdel-Wahab R, Wolff RA, Li D, Tweardy D, Phan AT, Hawk E, Javle M, Lee JS, Torres HA, Rashid A, Lenzi R, Hassabo HM, Abaza Y, Shalaby AS, Lacin S, Morris J, Patt YZ, Amos CI, Khaderi SA, Goss JA, Jalal PK, Kaseb AO. Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 15(11):1791-1799, 2017. e-Pub 2017. PMID: 28579181.
- Ettinger DS, Handorf CR, Agulnik M, Bowles DW, Cates JM, Cristea M, Dotan E, Eaton KD, Fidias PM, Gierada D, Gilcrease GW, Godby K, Iyer R, Lenzi R, Phay J, Rashid A, Saltz L, Schwab RB, Shulman LN, Smerage JB, Stevenson MM, Varadhachary GR, Zager JS, Zhen WK, Bergman MA, Freedman-Cass DA, Cancer Network NC. Occult primary, version 3.2014. J Natl Compr Canc Netw 12(7):996-74, 2014. e-Pub 2014. PMID: 24994917.
- Carlson H, Lenzi R, Raber MN, Varadhachary GR. A phase II study to evaluate the efficacy and toxicity of oxaliplatin in combination with gemcitabine in carcinoma of unknown primary. Int J Clin Oncol 18(2):226-31, 2013. e-Pub 2013. PMID: 22218909.
- McHenry M, Parker PA, Baile WF, Lenzi R. Voice analysis during bad news discussion in oncology: reduced pitch, decreased speaking rate and nonverbal communication of empathy. Support Care Cancer 20(5):1073-8, 2012. e-Pub 2012. PMID: 21573770.
- Ettinger DS, Agulnik M, Cates JM, Cristea M, Denlinger CS, Eaton KD, Fidias PM, Gierada D, Gockerman JP, Handorf CR, Iyer R, Lenzi R, Phay J, Rashid A, Saltz L, Shulman LN, Smerage JB, Varadhachary GR, Zager JS, Zhen WK, Cancer Network NC. Occult primary. J Natl Compr Canc Netw 9(12):1358-95, 2011. e-Pub 2011. PMID: 22157556.
- Varadhachary GR, Spector Y, Abbruzzese JL, Rosenwald S, Wang H, Aharonov R, Carlson HR, Cohen D, Karanth S, Macinskas J, Lenzi R, Chajut A, Edmonston TB, Raber MN. Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary. Clin Cancer Res 17(12):4063-70, 2011. e-Pub 2011. PMID: 21531815.
- Lenzi R, Baile WF, Costantini A, Grassi L, Parker PA. Communication training in oncology: results of intensive communication workshops for Italian oncologists. Eur J Cancer Care (Engl) 10.1111(2):2354-60, 2011. e-Pub 2011. PMID: 20477861.
- Costantini A, Baile WF, Lenzi R, Costantini M, Ziparo V, Marchetti P, Grassi L. Overcoming cultural barriers to giving bad news: feasibility of training to promote truth-telling to cancer patients. J Cancer Educ 24(3):180-5, 2009. e-Pub 2009. PMID: 19526404.
- Varadhachary GR, Talantov D, Raber MN, Meng C, Hess KR, Jatkoe T, Lenzi R, Spigel DR, Wang Y, Greco FA, Abbruzzese JL, Hainsworth JD. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol 26(27):4442-8, 2008. e-Pub 2008. PMID: 18802157.
- Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Wang H, Cleary KR, Staerkel GA, Charnsangavej C, Lano EA, Ho L, Lenzi R, Abbruzzese JL, Wolff RA. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26(21):3496-502, 2008. e-Pub 2008. PMID: 18640930.
- Hassan MM, Bondy ML, Wolff RA, Abbruzzese JL, Vauthey JN, Pisters PW, Evans DB, Khan R, Chou TH, Lenzi R, Jiao L, Li D. Risk factors for pancreatic cancer: case-control study. Am J Gastroenterol 102(12):2696-707, 2007. e-Pub 2007. PMID: 17764494.
- Hassan MM, Abbruzzese JL, Bondy ML, Wolff RA, Vauthey JN, Pisters PW, Evans DB, Khan R, Lenzi R, Jiao L, Li D. Passive smoking and the use of noncigarette tobacco products in association with risk for pancreatic cancer: a case-control study. Cancer 109(12):2547-56, 2007. e-Pub 2007. PMID: 17492688.
- Lenzi R, Edwards R, June C, Seiden MV, Garcia ME, Rosenblum M, Freedman RS. Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease < 1 cm) associated with ovarian cancer or primary peritoneal carcinoma. J Transl Med 5:66, 2007. e-Pub 2007. PMID: 18076766.
- Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, Abbruzzese JL. Metastatic patterns in adenocarcinoma. Cancer 106(7):1624-33, 2006. e-Pub 2006. PMID: 16518827.
- Li D, Jiao L, Li Y, Doll MA, Hein DW, Bondy ML, Evans DB, Wolff RA, Lenzi R, Pisters PW, Abbruzzese JL, Hassan MM. Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer. Carcinogenesis 27(1):103-11, 2006. e-Pub 2006. PMID: 15987714.
- Li D, Ahmed M, Li Y, Jiao L, Chou TH, Wolff RA, Lenzi R, Evans DB, Bondy ML, Pisters PW, Abbruzzese JL, Hassan MM. 5,10-Methylenetetrahydrofolate reductase polymorphisms and the risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 14(6):1470-6, 2005. e-Pub 2005. PMID: 15941958.
- Xiong HQ, Plunkett W, Wolff R, Du M, Lenzi R, Abbruzzese JL. A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol 55(6):559-64, 2005. e-Pub 2005. PMID: 15726370.
- Ettinger DS, Arnoletti JP, Gockerman JP, Handorf C, Havlin KA, Jacobs CD, Javle M, Kvols L, Lenzi R, Rashid A, Rhoades CA, Ridge JA, Saltz L, Shulman LN, Sondak VK, Thompson JA, Twardowski P, Zhen W, Cancer Network NC. Occult primary cancer clinical practice guidelines. J Natl Compr Canc Netw 3(2):214-33, 2005. e-Pub 2005. PMID: 19817031.
- Lenzi R, Baile WF, Berek J, Back A, Buckman R, Cohen L, Parker PA. Design, conduct and evaluation of a communication course for oncology fellows. J Cancer Educ 20(3):143-9, 2005. e-Pub 2005. PMID: 16122361.
- Wefel JS, Lenzi R, Theriault R, Buzdar AU, Cruickshank S, Meyers CA. 'Chemobrain' in breast carcinoma?: a prologue. Cancer 101(3):466-75, 2004. e-Pub 2004. PMID: 15274059.
- Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 100(11):2292-9, 2004. e-Pub 2004. PMID: 15160331.
- Weinbergh JS, Suki D, Hanbali F, Cohen ZR, Lenzi R, Sawaya R. Metastasis of esophageal carcinoma to the brain. Cancer 98(9):1925-33, 2003. e-Pub 2003.
- Cohen L, Baile WF, Henninger E, Agarwal SK, Kudelka AP, Lenzi R, Sterner J, Marshall GD. Physiological and psychological effects of delivering medical news using a simulated physician-patient scenario. J Behav Med 26(5):459-71, 2003. e-Pub 2003. PMID: 14593853.
- Tempero AM, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21(18):3402-8, 2003. e-Pub 2003.
- Melichar B, Lenzi R, Rosenblum M, Kudelka AP, Kavanagh JJ, Melicharova K, Templin S, Garcia ME, Abbruzzese JL, Freedman RS. Intraperitoneal fluid neopterin, nitrate, and tryptophan after regional administration of interleukin-12. J Immunother 26(3):270-6, 2003. e-Pub 2003.
- Pentz RD, Lenzi R, Holmes F, Khan MM, Verschraegen C. Discussion of the do-not-resuscitate order: a pilot study of perceptions of patients with refractory cancer. Support Care Cancer 10(8):573-8, 2002. e-Pub 2002. PMID: 12436216.
- Lenzi R, Rosenblum M, Verschraegen C, Kudelka AP, Kavanagh JJ, Hicks ME, Lang EA, Nash MA, Levy LB, Garcia ME, Platsoucas CD, Abbruzzese JL, Freedman RS. Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Mullerian carcinoma, gastrointestinal primary malignancies. Clin Cance rREs 8(12):3686-95, 2002. e-Pub 2002.
- Pisters PW, Wolff RA, Janjan NA, Cleary KR, Charnsangavej C, Crane CN, Lenzi R, Vauthey JN, Lee JE, Abbruzzese JL, Evans DB. Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. J Clin Oncol 20(10):2537-44, 2002. e-Pub 2002. PMID: 12011133.
- Baile WF, Lenzi R, Parker PA, Buckman R, Cohen L. Oncologists' attitudes toward and practices in giving bad news: an exploratory study. J Clin Oncol 20(8):2189-96, 2002. e-Pub 2002. PMID: 11956281.
- Crane CH, Abbruzzese JL, Evans DB, Wolff RA, Ballo MT, Delclos M, Milas L, Mason K, Charnsangavej C, Pisters PW, Lee JE, Lenzi R, Vauthey JN, Wong AB, Phan T, Nguyen Q, Janjan NA. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?. Int J Radiat Oncol Biol Phys 52(5):1293-302, 2002. e-Pub 2002. PMID: 11955742.
- Lenzi R, Yalcin S, Evans DB, Abbruzzese JL. Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy. Cancer Invest 20(4):464-72, 2002. e-Pub 2002. PMID: 12094541.
- Wolff RA, Evans DB, Gravel DM, Lenzi R, Pisters PW, Lee JE, Janjan NA, Charnsangavej C, Abbruzzese JL. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res 7(8):2246-53, 2001. e-Pub 2001. PMID: 11489798.
- Parker PA, Baile WF, de Moor C, Lenzi R, Kudelka AP, Cohen L. Breaking bad news about cancer: patients' preferences for communication. J Clin Oncol 19(7):2049-56, 2001. e-Pub 2001. PMID: 11283138.
- Janjan NA, Crane C, Feig BW, Cleary K, Dubrow R, Curley S, Vauthey JN, Lynch P, Ellis LM, Wolff R, Lenzi R, Abbruzzese J, Pazdur R, Hoff PM, Allen P, Brown T, Skibber J. Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. Am J Clin Oncol 24(2):107-12, 2001. e-Pub 2001. PMID: 11319280.
- Crane CH, Janjan NA, Abbruzzese JL, Curley S, Vauthey J, Sawaf HB, Dubrow R, Allen P, Ellis LM, Hoff P, Wolff RA, Lenzi R, Brown TD, Lynch P, Cleary K, Rich TA, Skibber J. Effective pelvic symptom control using initial chemoradiation without colostomy in metastatic rectal cancer. Int J Radiat Oncol Biol Phys 49(1):107-16, 2001. e-Pub 2001. PMID: 11163503.
- Crane CH, Antolak JA, Rosen II, Forster KM, Evans DB, Janjan NA, Charnsangavej C, Pisters PW, Lenzi R, Papagikos MA, Wolff RA. Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head. Int J Gastrointest Cancer 30(3):123-32, 2001. e-Pub 2001. PMID: 12540024.
- Crane CH, Janjan NA, Evans DB, Wolff RA, Ballo MT, Milas L, Mason K, Charnsangavej C, Pisters PW, Lee JE, Lenzi R, Vauthey JN, Wong A, Phan T, Nguyen Q, Abbruzzese JL. Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. Int J Pancreatol 29(1):9-18, 2001. e-Pub 2001. PMID: 11560155.
- Crane C, Janjan N, Evans D, Wolff R, Ballo M, Milas L, Mason K, Charnsangavej C, Pisters P, Lee J, Lenzi R, Vauthey J, Wong A, Phan T, Nguyen Q, Abbruzzese J. Toxicity and Efficacy of Concurrent Gemcitabine and Radiotherapy for Locally Advanced Pancreatic Cancer. Int J Gastrointest Cancer 29(1):9-18, 2001. e-Pub 2001. PMID: 12754400.
- Janjan NA, Breslin T, Lenzi R, Rich TA, Skibber J. Avoidance of colostomy placement in advanced colorectal cancer with twice weekly hypofractionated radiation plus continuous infusion 5-fluorouracil. J Pain Symptom Manage 20(4):266-72, 2000. e-Pub 2000. PMID: 11027908.
- Janjan NA, Crane CN, Feig BW, Cleary K, Dubrow R, Curley SA, Ellis LM, Vauthey J, Lenzi R, Lynch P, Wolff R, Brown T, Pazdur R, Abbruzzese J, Hoff PM, Allen P, Brown B, Skibber J. Prospective trial of preoperative concomitant boost radiotherapy with continuous infusion 5-fluorouracil for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 47(3):713-8, 2000. e-Pub 2000. PMID: 10837955.
- Pisters PW, Hudec WA, Lee JE, Raijman I, Lahoti S, Janjan NA, Rich TA, Crane CH, Lenzi R, Wolff RA, Abbruzzese JL, Evans DB. Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents. J Clin Oncol 18(4):860-7, 2000. e-Pub 2000. PMID: 10673529.
- Baile WF, Buckman R, Lenzi R, Glober G, Beale EA, Kudelka AP. SPIKES-A six-step protocol for delivering bad news: application to the patient with cancer. Oncologist 5(4):302-11, 2000. e-Pub 2000. PMID: 10964998.
- Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL. Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res 5(11):3403-10, 1999. e-Pub 1999. PMID: 10589751.
- Baile WF, Kudelka AP, Beale EA, Glober GA, Myers EG, Greisinger AJ, Bast RC, Goldstein MG, Novack D, Lenzi R. Communication skills training in oncology. Description and preliminary outcomes of workshops on breaking bad news and managing patient reactions to illness. Cancer 86(5):887-97, 1999. e-Pub 1999. PMID: 10463990.
- Pisters PW, Abbruzzese JL, Janjan NA, Cleary KR, Charnsangavej C, Goswitz MS, Rich TA, Raijman I, Wolff RA, Lenzi R, Lee JE, Evans DB. Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol 16(12):3843-50, 1998. e-Pub 1998. PMID: 9850029.
- Janjan NA, Payne R, Gillis T, Podoloff D, Libshitz HI, Lenzi R, Theriault R, Martin C, Yasko A. Presenting symptoms in patients referred to a multidisciplinary clinic for bone metastases. J Pain Symptom Manage 16(3):171-8, 1998. e-Pub 1998. PMID: 9769619.
- Ayoub JP, Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL. Unknown primary tumors metastatic to liver. J Clin Oncol 16(6):2105-12, 1998. e-Pub 1998. PMID: 9626210.
- Lenzi R, Kim EE, Raber MN, Abbruzzese JL. Detection of primary breast cancer presenting as metastatic carcinoma of unknown primary origin by 111In-pentetreotide scan. Ann Oncol 9(2):213-6, 1998. e-Pub 1998. PMID: 9553668.
- Lenzi R, Hess KR, Abbruzzese MC, Raber MN, Ordoñez NG, Abbruzzese JL. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma?. J Clin Oncol 15(5):2056-66, 1997. e-Pub 1997. PMID: 9164218.
- Baile WF, Lenzi R, Kudelka AP, Maguire P, Novack D, Goldstein M, Myers EG, Bast RC. Improving physician-patient communication in cancer care: outcome of a workshop for oncologists. J Cancer Educ 12(3):166-73, 1997. e-Pub 1997. PMID: 9376255.
- Abbruzzese JL, Abbruzzese MC, Lenzi R, Raber MN, Hess KR. Are time or intensity factors important to the definition of metastases of unknown origin?. J Natl Cancer Inst 88(7):462-3, 1996. e-Pub 1996. PMID: 8618241.
- Abbruzzese JL, Abbruzzese MC, Lenzi R, Hess KR, Raber MN. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol 13(8):2094-103, 1995. e-Pub 1995. PMID: 7636553.
- Abbruzzese JL, Abbruzzese MC, Hess KR, Raber MN, Lenzi R, Frost P. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol 12(6):1272-80, 1994. e-Pub 1994. PMID: 8201389.
- Lenzi R, Frost P, Abbruzzese JL. Modulation of cisplatin resistance by 2'-deoxy-5-azacytidine in human ovarian tumor cell lines. Anticancer Res 14(1A):247-51, 1994. e-Pub 1994. PMID: 7513143.
- Lenzi R, Raber MN, Frost P, Schmidt S, Abbruzzese JL. Phase II study of cisplatin, 5-fluorouracil and folinic acid in patients with carcinoma of unknown primary origin. Eur J Cancer 29A(11):1634, 1993. e-Pub 1993. PMID: 8217373.
- Lenzi R, Liu MH, Tarsetti F, Slott PA, Alpini G, Zhai WR, Paronetto F, Lenzen R, Tavoloni N. Histogenesis of bile duct-like cells proliferating during ethionine hepatocarcinogenesis. Evidence for a biliary epthelial nature of oval cells. Lab Invest 66(3):390-402, 1992. e-Pub 1992.
- Lenzi R, Alpini G, Liu MH, Rand JH, Tavoloni N. von Willebrand factor antigen is not an accurate marker of rat and guinea pig liver endothelial cells. Liver 10(6):372-9, 1990. e-Pub 1990.
- Alpini G, Lenzi R, Zhai WR, Slott PA, Liu MH, Sarkozi L, Tavolini N. Bile secretory function of intrahepatic biliary epithelium in in the rat. Am J Physiol 257(1 Pt 1):124-33, 1989. e-Pub 1989.
Review Articles
- Ettinger DS, Agulnik M, Cristea M, Eaton K, Fidias PM, Gockerman JP, Hameed O, Handorf C, Harris EI, Jacobs CD, Javle M, Khushalani NI, Kvols L, Lenzi R, Lewis NL, Rashid A, Saltz L, Shulman LN, Zager JS, Zhen W. Occult primary. J Natl Compr Canc Netw 6(10):1026-60, 2008. e-Pub 2008. PMID: 19176200.
- Varadhachary GR, Abbruzzese JL, Lenzi R. Diagnostic strategies for unknown primary cancer. Cancer 100(9):1776-85, 2004. e-Pub 2004. PMID: 15112256.
- Crane CH, Wolff RA, Abbruzzese JL, Evans DB, Milas L, Mason K, Charnsangavej C, Pisters PW, Lee JE, Lenzi R, Lahoti S, Vauthey JN, Janjan NA. Combining gemcitabine with radiation in pancreatic cancer: understanding important variables influencing the therapeutic index. Semin Oncol 28(3 Suppl 10):25-33, 2001. e-Pub 2001. PMID: 11510031.
- Wolff RA, Chiao P, Lenzi R, Pisters PW, Lee JE, Janjan NA, Crane CH, Evans DB, Abbruzzese JL. Current approaches and future strategies for pancreatic carcinoma. Invest New Drugs 18(1):43-56, 2000. e-Pub 2000. PMID: 10830140.
- Baile WF, Glober GA, Lenzi R, Beale EA, Kudelka AP. Discussing disease progression and end-of-life decisions. Oncology (Williston Park) 13(7):1021-31; discussion 1031-6, 1038, 1999. e-Pub 1999. PMID: 10442349.
- Freedman RS, Lenzi R, Kudelka AP, Lawrence DD, Rosenblum M, Platsoucas CD. Intraperitoneal immunotherapy of peritoneal carcinomatosis. Cytokines Cell Mol Ther 4(2):121-40, 1998. e-Pub 1998. PMID: 9681251.
- Evans DB, Lee JE, Pisters PW, Charnsangavej C, Ellis LM, Chiao PJ, Lenzi R, Abbruzzese JL. Advances in the diagnosis and treatment of adenocarcinoma of the pancreas. Cancer Treat Res 90:109-25, 1997. e-Pub 1997. PMID: 9367080.
- Abbruzzese JL, Lenzi R, Raber MN, Pathak S, Frost P. The biology of unknown primary tumors. Semin Oncol 20(3):238-43, 1993. e-Pub 1993. PMID: 8503019.
Professional Educational Materials
- Lin EH, Burton A, Lenzi R, Espirito J, Anthony L, Karp D. Cancer Matrix Manual. Advanced Medical Publishing, Inc, 2006.
Abstracts
- Bhulani N, Xiao L, Hassan M, Lenzi R. Predictors of no-show among international patients with cancer: A 4-year analysis. J Clin Oncol 35, 2017. e-Pub 2017.
- Botrus G, Shalaby AS, Kaseb AO, Lenzi R, Abdel-Wahab R, Wolff RA, Hassan M. The protective effect of hormonal intake on risk of hepatocellular carcinoma in the United States. J Clin Oncol 33(suppl), 2015. e-Pub 2015.
- Raghav KPS, Mhadgut H, Lei X, Overman MJ, Lenzi R, Raber MN, Varadhachary G. Cancer of unknown pirmary in adolescents and young adults: clinicopathologic features, prognostic factors, and survival outcomes. J Clin Oncol 32(5S), 2014. e-Pub 2014.
- Lenzi R, Coleman M, Xiao L, Abdel-Wahab R, Hassan M. Retrospective study to evaluate variables predicting no-show international patients. J Clin Oncol 32(Suppl), 2014. e-Pub 2014.
- Varadhachary GR, Siddharth K, Hainsworth JD, Wang H, Carlson HR, Lenzi R, Abbruzzese JL, Raber MN, Greco FA. Patients with carcinoma of unknown primary and "colon cancer profile": Cllinicopathologic features and survival data. Proc Am Soc Clin Onc, 2012. e-Pub 2012.
- Stemke Hale K, Wang HW, Karanth S, Raber MN, Carlson HR, Lenzi R, Abbruzzese JL, Mills GB, Varadhachary GR. Mutation profling in patients with carcinoma of unknown primary using the Sequenom MassARRAY system. J Clin Oncol Suppl, 2012. e-Pub 2012.
- Lenzi R, Parker PA, Baile WF, McHenry M. Voice analysis during bad news discussion in oncology: decreased speaking rate, pitch, and nonverbal communication of empathy. J Clin Oncol 29(Suppl), 2011. e-Pub 2011.
- Carlson HR, Karanth S, Zarzour MA, Lenzi R, Raber MN, Varadhachary GR. Patients with carcinoma of unknown primary with isolated carcinomatosis on presentation: clinicopathologic features and survival data. J Clin Oncol 29(Suppl), 2011. e-Pub 2011.
- Varadhachary GR, Edmonston TB, Karanth S, Carlson HR, Lebanony D, Rosenwald S, Lenzi R, Spector Y, Cohen D, Raber MN. Prospective gene signature study using microRNA to predict the tissue of origin (ToO) in patients with cancer of unknown primary site (CUP). ASCO Annual Meeting Proceedings 28(15S), 2010. e-Pub 2010.
- Parker PA, Baile W, Cohen I, Abbruzzese J, Varadhachary G, Ho L, LaPushin T, Dayao P, Lenzi R. Illness uncertainty, sense of coherence, and psychosocial adjustment in patients with pancreatic cancer. Annals of Behavioral Medicine 37S:51, 2009. e-Pub 2009.
- Lenzi R, Rashid A, Ordonez N, Raber MN, Varadhachary GR, Erlander M, Abbruzzese JL. Gene profiling validation of molecular markers in patients with cancer of unknown pirmary (CUP). ASCO Annual Meeting Proceedings 25(18S):21130, 2007. e-Pub 2007.
- Varadhachary GR, Talanov D, Jatkoe T, Rashid A, Lenzi R, Chadha R, Baden J, Wang Y, Abbruzzese JL, Raber MN. Prospective study of a 10-gene molecular assay to predict tissue of origin in patients with carcinomas of unknown primary (CUP). ASCO Annual Meeting Proceedings 25(18S):21096, 2007. e-Pub 2007.
- Rashid A, Hess KR, Lenzi R, Raber MN, Abbruzzese JL, Varadhachary GR. Overexpression and prevalence of molecular markers in patients with cancer of unknown primary (CUP). ASCO Annual Meeting Proceedings 23(16S):9683, 2005. e-Pub 2005.
- Varadhachary GR, Blais JC, Raber MN, Lenzi R, Hoff PM, Abbruzzese JL. Phase II study to evaluate the efficacy and toxicity of oxaliplatin in combination with gemcitabine (GEMOX) in cancer of unknown primary (CUP). ASCO Annual Proceedings 23(16S):4140, 2005. e-Pub 2005.
- Parker PA, Lenzi R, Cohen L, Berek J, Back A, Buckman R, Baile WF. Evaluation of an interactive communication skills workshop for oncology fellows. Psycho-Oncology 12(4):S171, 2003. e-Pub 2003.
- Xiong H, Du M, Wolff R, Lenzi R, Dumas P, Lassere Y, Plunkett W, Abbruzzese J. Parmacology study of celecoxib in combination with gemcitabine for advanced pancreatic cancer. Proc Am Soc Clin Onc, 2002. e-Pub 2002.
- Lenzi R, Claire V, Andrzej K, Vincent M, Wolff R, Abbruzzese J, Cristofanilli M, Loyer E, Hu W, Kavanaugh J, Rubin E. New escalation scheme for phase I study of drug combination: 9-nitro-20(S)-camptothecin (RFS 2000) with cisplatin for patients (pts) with advanced malignancies. Proc Am Soc Clin Onc, 2002. e-Pub 2002.
- Baile W, Lenzi R, Parker P, Cohen L, Buckman R. Oncologists' attitudes and practices toward breaking bad news: a preliminary study. Proc Am Soc Clin Onc, 2002. e-Pub 2002.
- Wolff RA, Evans DB, Crane C, Cleary K, Lenzi R, Abbruzzese JL, Charnsangavej C, Tamm E, Janjan N, Delclos M, Vauthey JN, Lee J, Pisters P. Initial results of preoperative gemcitabine (GEM)-based chemoradiation for resectable pancreatic adenocarcinoma, 2002. e-Pub 2002.
- Wolff RA, Evans DB, Gravel DM, Lenzi R, Pisters PW, Lee JE, Janjan NA, Charnsangavej C, Abbruzzese JL. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res 7(8):2246-53, 2001. e-Pub 2001. PMID: 11489798.
- Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL. Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res 5(11):3403-10, 1999. e-Pub 1999. PMID: 10589751.
- Lenzi R, Hess KR, Abbruzzese MC, Raber MN, Ordoñez NG, Abbruzzese JL. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma?. J Clin Oncol 15(5):2056-66, 1997. e-Pub 1997. PMID: 9164218.
- Evans DB, Lee JE, Pisters PW, Charnsangavej C, Ellis LM, Chiao PJ, Lenzi R, Abbruzzese JL. Advances in the diagnostics and treatment of adenocarcinoma of the pancreas. Can Treat & Res(90):109-24, 1997. e-Pub 1997.
- Baile WF, Lenzi R, Kudelka A, Novack D, Goldstein M, Maguire P, Meyers E, Bast R. Improving the physician-patient relationship in cancer care: Report of a workshop. Psycho-Oncology 5(30):178, 1996. e-Pub 1996.
- Hess K, Abbruzzese MC, Lenzi R, Raber M, Abbruzzese JL. Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Proc Am Soc Clin Onc(15):452, 1996. e-Pub 1996.
- Kavanagh JJ, Tresukosol D, De Leon CG, Edwards CL, Freedman RS, Hord M, Howell E, Lenzi R, Krakoff IH, Kudelka AP. Phase II study of prolonged oral etoposide in refractory ovarian cancer. Int J Gynecol Cancer 5(5):351-354, 1995. e-Pub 1995. PMID: 11578503.
- Abbruzzese JL, Abbruzzese M, Lenzi R, Hess KR, Raber M. Latent primary malignancies (LPMs): Diagnostic evaluation, common primaries and survival patterns of patients presenting with unknown primary tumors (UPTs). Proc Am Soc Clin Onc(14):435, 1995. e-Pub 1995.
- Lenzi R, Frost P, Abbruzzese JL. Modulation of cisplatin resistance by 2'-deoxy-5-azacytidine in human ovarian tumor cell lines. Anticancer Res 14(1A):247-51, 1994. e-Pub 1994. PMID: 7513143.
- Lenzi R, Raber M, Abbruzzese M, Abbruzzese JL. Poorly differentiated (PDC) and undifferentiated (UDC) carcinomas of unknown primary (UP): Incidence of favorable subsets, response to chemotherapy and survival. Proc Am Soc Clin Onc(13):402, 1994. e-Pub 1994.
- Kudelka A, Edwards C, Freedman D, Tresukol D, Gonzalez de Leon C, Hord M, Howell E, Krakoff I, Dugan T, Lenzi R, Kavanagh J. A Phase II study of prolonged oral VP-16 in women with refractory epithelial ovarian carcinoma. Proc Am Soc Clin Onc(13):279, 1994. e-Pub 1994.
- Lenzi R, Luca M, Lee-Jackson D, Gutman M, Fidler IJ, bari-Eli M. The metastatic potential of human melanoma cell lines is independant of p53 mutations in exxons 5-9. Proc Am Assoc Can Res(35):252, 1994. e-Pub 1994.
- Lenzi R, Abbruzzese JL, Abbruzzese M, Frost P, Raber MN. Diagnostic evaluation of patients with metastatic tumors of unknown primary (UPT): A standardized approach. Proc Am Soc Clin One(12):398, 1993. e-Pub 1993.
- Lenzi R, Meyers CA. Artificial intelligence (neural networks) and discriminate analysis in the evaluation of neuropsychological abnormalities in cancer patients. Proc Am Assoc Can Res(34):233, 1993. e-Pub 1993.
- Abbruzzese JL, Abbruzzese M, Hess HP, Lenzi R, Raber M, Frost P. Unknown primary carcinoma (UPC): Analysis of the natural history based on a clinical evaluation of 500 consecutive patients. Proc Am Soc Clin Onc(12):401, 1993. e-Pub 1993.
- Lenzi R, Raber MN, Frost P, Schmidt S, Abbruzzese JL. Phase II study of cisplatin, 5-fluorouracil and folinic acid in patients with carcinoma of unknown primary origin. Eur J Cancer 29A(11):1634, 1993. e-Pub 1993. PMID: 8217373.
- Abbruzzese JL, Sidransky D, Abbruzzese M, Lenzi R, Raber M, Frost P. Unknown primary carcinoma (UPT): A novel biologic perspective. Proc Am Assoc Clin One(11):354, 1992. e-Pub 1992.
- Lenzi R, Abbruzzese M, Abbruzzese JL, Frost P, Raber M. Diagnostic evaluation of patients (pts) with metastatic tumors of unknown primary (UPT). Proc Am Assoc Clin One(11):354, 1992. e-Pub 1992.
- Lenzi R, Abbruzzese J, Hunt B, Jackson D, Frost P. Reversal of cisplatinum (Cddp) resitance by 5-Aza-2'-Deoxycytidine (DAC) in human ovarian cell lines. Proc Am Assoc Can Res(33):479, 1992. e-Pub 1992.
- Lenzi R, Liu MH, Lenzen R, Han T, Alpini G, Tavoloni N. Distribution of glucose-6-phosphatase activity in normal, hyperplastic, and preneoplastic rat liver. Virchows Arch B Cell Pathol Incl Mol Pathol 61(4):279-87, 1991. e-Pub 1991. PMID: 1685820.
- Lenzi R, Abbruzzese J, Amato R, Raber M, Frost P. Cisplatin (cOOP), 5-flurouracil (5-FU) and folinic acid (FA) for the treatment of carcinoma of unknown primary. A Phase II study. Proc Am Soc Clin One(10):301, 1991. e-Pub 1991.
- Liu MH, Lenzi R, Alpini G, Han T, Tavoloni N. Oval cells are not the precursors of hepatocellular carcinoma induced by ethionine feeding in SO rats. Proc Am Assoc Can Res(31):150, 1990. e-Pub 1990.
- Alpini G, Lenzi R, Zhai WR, Liu MH, Slott PA, Paronetto F, Tavoloni N. Isolation of a nonparenchymal liver cell fraction enriched in cells with biliary epithelial phenotypes. Gastroenterology 97(5):1248-60, 1989. e-Pub 1989. PMID: 2477298.
- Lenzi R, Liu MH, Tavoloni N. Glucose-6-phosphatase (G-6-P) activity in hyperplastic, a well as preneoplastic, bile duct-like (oval) cells. Hepatology(9):143, 1989. e-Pub 1989.
- Alpini G, Lenzi R, Slott PA, Tavoloni N. Proliferation of bile duct-like structures in the rat: An experimental strategy to study transport function of the intrahepatic biliary epithelium. Gastroenterology(94):A521, 1988. e-Pub 1988.
- Lenzi R, Liu MH, Thung SN, Alpini G, Slott PA, Tavoloni N. Histologic, immunohistochemical, and functional characteristics of oval cells during chemical hepatocarcinogenesis. Hepatology(8):59, 1988. e-Pub 1988.
- Alpini G, Lenzi R, Sarkozi L, Tavoloni N. Biliary physiology in rats with bile ductular cell hyperplasia. Evidence for a secretory function of proliferated bile ductules. J Clin Invest 81(2):569-78, 1988. e-Pub 1988. PMID: 2448343.
- Lenzi R, Alpini G, Potter BJ, Tavoloni N. Cytokeratin (CK) distribution in normal and hyperaplastic rat liver. Hepatology(8):323, 1988. e-Pub 1988.
- Lenzi R, Alpini G, Rand JH, Tavoloni N. Immunolocalization of von Willebrand factor enzymatic phenotypes of proliferative bile duct-like cells in carcinogen and non-carcinogen fed rats. Hepatology(7):415, 1987. e-Pub 1987.
- Alpini G, Lenzi R, Brownell M, Tovoloni N. Isolation and characterazatiion of biliary epithelial cells from rats with bile ductular cell hyperplasia. Hepatology(6):349, 1986. e-Pub 1986.
- Lenzi R, Miller CH, Hilagartner, Aledort LM. Characterization of Factor VII and von Willebrand Factor Inhibitors Absorbed on Protein A Staphylococci: Loss of Time Dependency and Blocking of Hemophilic Plasma. Blood 68(5):1:349a, 1986. e-Pub 1986.
Book Chapters
- Lenzi R. Unknown primary carcinoma. In: Primary Care: A Collaborative Practice. 4th. Mosby Inc., Affiliate of Elsevier Inc, 2013.
- Lenzi R. Unknown primary carcinoma. In: Primary Care: A Collaborative Practice. 3rd. Mosby, 1349-1352, 2008.
- Glover KY, Varadhachary GR, Lenzi R, Raber MN, Abbruzzese JL. Carcinoma of unknown primary. In: Abeloff's Clinical Oncology. 4th. Churchill Livingstone, 2057-2074, 2008.
- Varadhachary GR, Lenzi R. Radiographic studies, endoscopy, and serum tumor markers in the diagnostic evaluation of carcinomas of unknown primary site. In: Carcinoma of Unknown Primary Site. Taylor and Francis Group, 11-22, 2006.
- Lenzi R, Culine S. Prognostic considerations in patients with unknown primary carcinoma. In: Carcinoma of Unknown Primary Site. Taylor and Francis Group, 61-75, 2006.
- Lenzi R, Baile WF, Rodary C, Parker PA. Psychosocial aspects of cancer of unknown primary site. In: Carcinoma of Unknown Primary Site. Taylor and Francis Group, 175-190, 2006.
- Lenzi R. Unknown Primary Carcinoma. In: Primary Care: A Collaborative Practice. Mosby, Inc, Affiliate of Elsevier Inc, 2005.
- Weinberg JS, Lenzi R, Gokaslan ZL. Brain metastasis from upper gastrointestinal tract cancers: esophageal, gastric, hepatic, gallbladder, and pancreatic. In: Intracranial Metastases: Current Managment Strategies. Blackwell Futura, 362-80, 2004.
- Lenzi R. Unknown primary carcinoma. In: Primary Care: A Collaborative Practice. 5th. Mosby Inc., Affiliate of Elsevier Inc.
Letters to the Editor
- Lenzi R, Rand JH, Spiera H. Anticardiolipin antibodies in pregnant patients with systemic lupus erythematosus. N Engl J Med 314: 1392-3, 1986.
Patient Reviews
CV information above last modified July 22, 2026